ACTH and serum cortisol decreased during concomitant relacorilant and octreotide LAR treatment (Figure 4A), suggestive of an increased effect of octreotide LAR due to upregulation of SSTR2 without tumor shrinkage. Here, POMC is linked to neoplasm.